Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Island Pharmaceuticals Ltd ( (AU:ILA) ) has provided an announcement.
Island Pharmaceuticals Ltd has been granted a US patent for the use of Galidesivir in treating SARS-CoV-2, extending its patent protection until July 2042. This development strengthens Island’s intellectual property portfolio and supports Galidesivir’s potential as a broad-acting antiviral, aligning with the company’s strategy to advance its regulatory pathway for combating the Marburg virus.
More about Island Pharmaceuticals Ltd
Island Pharmaceuticals Ltd is an Australian antiviral drug development company focused on addressing urgent viral diseases, public health, or biosecurity threats. The company is executing a dual development strategy for its assets, ISLA-101 and Galidesivir, targeting unmet medical needs in viruses such as Ebola, Marburg, MERS, Zika, and Yellow fever.
Average Trading Volume: 773,349
Technical Sentiment Signal: Buy
Current Market Cap: A$146.6M
See more data about ILA stock on TipRanks’ Stock Analysis page.